Joseph P.  Hagan net worth and biography

Joseph Hagan Biography and Net Worth

Mr. Hagan joined Regulus in January 2016 as Chief Operating Officer, Principal Financial Officer and Principal Accounting Officer and was appointed to President and Chief Executive Officer in May 2017. Mr. Hagan’s career includes roles as the Executive Vice President, Chief Financial Officer and Chief Business Officer of Orexigen Therapeutics, Inc., Managing Director of Amgen Ventures and head of corporate development for Amgen Inc. Mr. Hagan has led numerous strategic and financing transactions including the acquisitions of Immunex and Tularik and the spinout of Novantrone and Relyspa, as well as many other business development efforts totaling over $15 billion in value. Before joining Amgen, Mr. Hagan spent five years in the bioengineering labs at Genzyme and Advanced Tissue Sciences. Mr. Hagan currently serves on the board of directors of Zosano Pharma, a publicly traded biotechnology company. He received an M.B.A. from Northeastern University and a B.S. in Physiology and Neuroscience from the University of California, San Diego

What is Joseph P. Hagan's net worth?

The estimated net worth of Joseph P. Hagan is at least $129,073.12 as of January 18th, 2024. Mr. Hagan owns 57,112 shares of Regulus Therapeutics stock worth more than $129,073 as of April 23rd. This net worth approximation does not reflect any other assets that Mr. Hagan may own. Additionally, Mr. Hagan receives an annual salary of $920,730.00 as CEO at Regulus Therapeutics. Learn More about Joseph P. Hagan's net worth.

How old is Joseph P. Hagan?

Mr. Hagan is currently 55 years old. There are 3 older executives and no younger executives at Regulus Therapeutics. Learn More on Joseph P. Hagan's age.

What is Joseph P. Hagan's salary?

As the CEO of Regulus Therapeutics Inc., Mr. Hagan earns $920,730.00 per year. Learn More on Joseph P. Hagan's salary.

How do I contact Joseph P. Hagan?

The corporate mailing address for Mr. Hagan and other Regulus Therapeutics executives is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. Regulus Therapeutics can also be reached via phone at (858) 202-6300 and via email at [email protected]. Learn More on Joseph P. Hagan's contact information.

Has Joseph P. Hagan been buying or selling shares of Regulus Therapeutics?

Joseph P. Hagan has not been actively trading shares of Regulus Therapeutics in the last ninety days. Most recently, Joseph P. Hagan sold 14,580 shares of the business's stock in a transaction on Thursday, January 18th. The shares were sold at an average price of $1.19, for a transaction totalling $17,350.20. Following the completion of the sale, the chief executive officer now directly owns 57,112 shares of the company's stock, valued at $67,963.28. Learn More on Joseph P. Hagan's trading history.

Who are Regulus Therapeutics' active insiders?

Regulus Therapeutics' insider roster includes Christopher Aker (VP), Denis Drygin (Insider), and Joseph Hagan (CEO). Learn More on Regulus Therapeutics' active insiders.

Are insiders buying or selling shares of Regulus Therapeutics?

During the last twelve months, insiders at the biopharmaceutical company sold shares 2 times. They sold a total of 20,048 shares worth more than $23,857.12. The most recent insider tranaction occured on January, 18th when CFO Crispina Calsada sold 5,468 shares worth more than $6,506.92. Insiders at Regulus Therapeutics own 8.4% of the company. Learn More about insider trades at Regulus Therapeutics.

Information on this page was last updated on 1/18/2024.

Joseph P. Hagan Insider Trading History at Regulus Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/18/2024Sell14,580$1.19$17,350.2057,112View SEC Filing Icon  
1/26/2022Buy100,000$0.22$22,000.00View SEC Filing Icon  
5/17/2021Sell4,186$0.89$3,725.54316,292View SEC Filing Icon  
2/16/2021Sell4,144$1.72$7,127.68485,756View SEC Filing Icon  
8/14/2020Sell4,245$0.60$2,547.00222,088View SEC Filing Icon  
5/15/2020Sell4,426$0.63$2,788.38226,333View SEC Filing Icon  
2/18/2020Sell4,324$0.83$3,588.92230,759View SEC Filing Icon  
1/2/2020Sell8,345$0.97$8,094.65235,083View SEC Filing Icon  
11/14/2019Sell5,838$0.64$3,736.32243,428View SEC Filing Icon  
10/1/2019Sell8,743$0.68$5,945.24249,266View SEC Filing Icon  
8/15/2019Sell4,375$0.55$2,406.25View SEC Filing Icon  
7/1/2019Sell5,783$1.31$7,575.73262,384View SEC Filing Icon  
5/16/2019Sell39,352$1.22$48,009.44307,519View SEC Filing Icon  
5/7/2019Buy33,194$1.08$35,849.5264,542View SEC Filing Icon  
4/1/2019Sell5,842$0.98$5,725.1631,348View SEC Filing Icon  
7/25/2017Buy219,780$0.91$199,999.80241,297View SEC Filing Icon  
3/3/2016Buy10,000$7.19$71,900.0010,000View SEC Filing Icon  
See Full Table

Joseph P. Hagan Buying and Selling Activity at Regulus Therapeutics

This chart shows Joseph P Hagan's buying and selling at Regulus Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Regulus Therapeutics Company Overview

Regulus Therapeutics logo
Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $2.26
Low: $2.13
High: $2.34

50 Day Range

MA: $2.14
Low: $1.38
High: $2.88

2 Week Range

Now: $2.26
Low: $1.08
High: $3.79

Volume

67,124 shs

Average Volume

2,482,327 shs

Market Capitalization

$147.94 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.56